Aclarion Inc. (NASDAQ: ACON) Provides Comprehensive 2025 Update and 2026 Outlook
BROOMFIELD, Colo., Jan. 08, 2026 (GLOBE NEWSWIRE) — Aclarion, Inc. (NASDAQ: ACON), a commercial-stage healthcare technology company focused on chronic low back pain treatment, has released its financial and operational update for 2025. The report highlights significant growth indicators, a strong financial position, and strategic plans for advancing its proprietary Nociscan platform as it heads into 2026.
Impressive Growth in Nociscan Scan Volumes
In 2025, Aclarion achieved a remarkable 69% year-over-year growth in Nociscan scan volumes. Notably, the fourth quarter of 2025 saw a substantial 114% increase year-over-year, marking the third consecutive quarter of growth. This growth extends across key regions, including the U.S., UK, and E.U.
To bolster its market presence, Aclarion has made strategic advancements, including:
- The addition of 9 new imaging centers in 2025.
- The integration of 22 new physician users.
- Expansion of its team through key leadership hires in the U.S. and UK.
Strategic and Operational Highlights
Aclarion has continued developing its Nociscan platform, focusing on:
- Clinical validation and readiness.
- Enhancing customer engagement initiatives.
- Strengthening clinical evidence supporting Nociscan's economic value.
- Fostering relationships with healthcare providers and payors.
The company has also expanded its intellectual property portfolio, with 4 new issued patents in 2025, bringing the total to 52 issued patents worldwide.
Clinical Trial and Product Development
Aclarion is committed to clinical validation via its ongoing CLARITY trial, which commenced in 2025 at seven activated sites. The company aims to enroll approximately 25% of patients in this trial by the end of the second quarter of 2026, with initial readouts expected in Q3 2026.
Aclarion's 2025 publications have demonstrated the clinical utility of the Nociscan technology:
- A cost-effectiveness analysis published in ClincoEconomics concluded that Nociscan is more effective and less costly than traditional methods, saving $1,712 per patient.
- An article in the International Journal of Spine Surgery showcased the technology's capabilities through a successful case study.
Financial Highlights
As of December 31, 2025, Aclarion reported a strong financial position with $12.0 million in cash and no debt. The company raised over $22.0 million in equity financing throughout 2025, which has significantly enhanced its operational runway into 2027.
As of the end of 2025, Aclarion had 854,371 common shares and 28,000 prefunded warrants outstanding, amounting to approximately $13.65 per share in cash on a fully diluted basis.
Management Commentary
Brent Ness, CEO of Aclarion, expressed optimism about the company’s trajectory: “We are pleased with the progress Aclarion has made in strengthening our financial position, expanding clinical traction, and advancing Nociscan toward broader adoption. The notable increase in scan volume, particularly in the UK, reflects significant momentum and investor confidence. Our focus remains on executing our strategic plans to create long-term value.”
About Aclarion, Inc.
Aclarion is at the forefront of healthcare technology, utilizing Magnetic Resonance Spectroscopy (MRS) to optimize treatments for chronic low back pain. The company's Nociscan platform leverages data from MRIs to aid physicians in differentiating between painful and non-painful discs, ultimately streamlining clinical decision-making.
For more information about Aclarion and its innovative solutions, visit www.aclarion.com.